BrianIRiniMDFASCO

PubMed

• 651 citations
  Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
  Toni K. Choueiri, Bernard Escudier, Thomas Powles, Nizar M. Tannir, Paul N. Mainwaring
  The Lancet. Oncology. 2016-07-01
• 1578 citations
  Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From ...
  Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan, Mark Andrew Warren, Ali Reza Golshayan
  Journal of Clinical Oncology. 2009-12-01
• 424 citations
  Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, ...
  Thomas Powles, Elizabeth R. Plimack, Denis Soulières, T. Waddell, Viktor Stus
  The Lancet. Oncology. 2020-12-01

Journal Articles

• Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Ca...  
  Michael B Atkins, Mario Sznol, Robert J Motzer, Richard W Joseph, Thomas Hutson, John Hainsworth, W Kimryn Rathmell, Brian I Rini, David F McDermott, Toni K Choueiri, ..., Nature
• The Association Between Facility Case Volume and Overall Survival in Patients with Metastatic Renal Cell Carcinoma in the Targeted Therapy Era  
  Timothy Gilligan, Jorge A Garcia, Brian I Rini, Urologic Oncology
• Treatment Selection for Men with Metastatic Prostate Cancer Who Progress on Upfront Chemo‐Hormonal Therapy  
  Vadim Koshkin, Prateek Mendiratta, Brian I Rini, Pedro Barata, Christos Kyriakopoulos, Hamid Emamekhoo, Timothy Gilligan, The Prostate
• Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Carcinoma  
  Michael B Atkins, Thomas Hutson, Mario Sznol, Toni K Choueiri, Sumanta K Pal, Richard W Joseph, John Hainsworth, W Kimryn Rathmell, David F McDermott, Robert J Motzer,..., Nature
• CALGB 90206: A Randomized Phase III Trial of Interferon-alpha or Interferon-alpha Plus anti-VEGF Antibody (bevacizumab, Avastin®) in Metastatic Renal Cell Carcinoma.  
  Rini BI, Halabi S, Taylor J, Small ES and. Schilsky RL, Clinical Cancer Research 10(8): 2584-6
• Clinical trials in patients with biochemically relapsed prostate cancer.  
  Lin AM, Rini BI, Small EJ, British Journal of Urology 97: 905-10
• Recent Clinical Development of Dendritic Cell-based Immunotherapy for Prostate Cancer.  
  Rini BI, Expert Opin Biol Therapy (11): 1729-34
• Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived GM-CSF.  
  Rini, BI, Wadhwa, M, Bird, C, Small ES, Gaines-Das R, Thorpe R, Cytokine 29(2): 56-66
• Long-term Follow Up of Non-myeloablative Allogeneic Stem Cell Transplantation for Renal Cell Carcinoma: The University of Chicago Experience.  
  Artz AA, Van Beisen K, Zimmerman T, Gajewski TF, Rini BI, Hu HS, Stadler WM, Vogelzang NJ, Blood and Bone Marrow Transplant 35(3): 253-60
• Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in ren...  
  Stadler WM, Rosner G, Small E, Hollis D, Rini BI, Zaentz SD, Mahoney J, Ratain MJ, Journal of Clinical Oncology 23(16): 3726-32
• VEGF-Targeted Therapy in Metastatic Renal Cell Carcinoma: Biology, Clinical Results and Future Development.  
  Rini BI, Sosman JA, Motzer RJ, British Journal of Urology 96(3): 286-290
• APC8015 (Provenge?) in Patients with Androgen-dependent, Biochemically-relapsed Prostate Cancer.  
  Rini BI, Beinart G, Weinberg VW, Small EJ, Clinical Prostate Cancer 4(1): 55-60
• Multi-targeted Tyrosine Kinase Inhibitor SU11248 Shows a High Level of Antitumor Activity in Patients with Metastatic Renal Cell Carcinoma.  
  Motzer RJ, Michaelson MD, Redman BG, Hudes GO, Wilding G, Figlin RA, Ginsberg MS, Kim S, Baum C, DePrimo S, Li J, Bello C, Theuer C, George D, Rini BI, Journal of Clinical Oncology 24(1): 1-8
• Inhibiting the VEGF signaling pathway: New trials focus on combination therapy with antiangiogenic agents.  
  Rini BI, Kidney Cancer Journal 3(1): 20-24
• Molecularly targeted therapy in renal cell carcinoma.  
  Rathmell K, Wright T, Rini, BI, Expert Rev. Anticancer Therapy 5(6): 1-10
• Clinical Response to VEGF-targeted Therapy in Metastatic Renal Cell Carcinoma: Impact of Patient Characteristics and VHL Gene Mutation.  
  Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, Fong K, Simko J, Small EJ, Waldman FM, British Journal of Urology 98(4): 756-62
• Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II Study.  
  Rini BI, Halabi S, Barrier R, Margolin K, Avigan D, Logan T, Stadler WM, McCarthy PL, Linker CA, Small EJ, Blood and Bone Marrow Transplant 12(7): 778-85
• Pivotal Study of Sunitinib Malate (SU11248) Shows Efficacy in Patients with Metastatic Renal Cell Carcinoma.  
  Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg, Bacik J, Kim ST, Baum CM, Michaelson MD, JAMA 295(21): 2516-24
• A Phase II Trial of Imatinib Mesylate in Patients with Biochemical Relapse of Prostate Cancer after Definitive Local Therapy.  
  Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ, British Journal of Urology 98(4): 763-9
• Sorafenib.  
  Rini BI, Expert Opinion Pharmacotherapy 7(4): 453-61
• Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T...  
  Harlin H, Artz AS, Mahowald M, Rini BI, Zimmerman T, Vogelzang NJ, Gajewski TF, Bone Marrow Transplant 33(5): 491-7
• The Potential for Prostate Cancer Immunotherapy.  
  Rini BI, Small EJ, Critical Reviews in Oncology and Hematology 27(46 Suppl):117-25
• Technology evaluation: APC-8015.  
  Rini BI, Current Opinion in Molecular Therapeutics 4(1): 76-79
• Docetaxel, Estramustine Plus Trastuzumab in Patients with Metastatic, Androgen-Independent Prostate Cancer.  
  Rini BI, Scott T. and Small EJ, Physician’s Education Resource
• A Phase II Trial of Weekly Intravenous Gemcitabine and Cisplatin with Prolonged Continuous Infusion 5-Fluourouracil in Patients with Metastatic Renal Cell Carcinoma.  
  George CM, Vogelzang NJ, Rini BI, Stadler WM, Annals of Oncology 13(1): 116-20
• Join now to see all

Books/Book Chapters

• Textbook of Uncommon Cancer. 
  Chapter: Uncommon Tumors of the Kidney 
  Khaled Ali, Ming Zhou, Steve Campbell, Ronald M. Bukowski and Brian I. RiniEditors: Derek Raghavan, Charles D. Blanke, David H. Johnson, Paul L. Moots, Gregory H. Reaman, Peter G. Rose.John Wiley & Sons, IncEdition 4,
• Renal Cell Carcinoma: Clinical Management. 
  Campbell SC, Rini BISpringer Science, Human Press, New York, NY
• Cancer Management: A Multi-disciplinary Approach. 
  Chapter: Urothelial and kidney cancers 
  Rini BI, Hurwitz MEdition 11,
• Prostate Cancer: A Clinical Guide. 
  Chapter: Biochemical recurrence of prostate cancer 
  Garcia JA, Rini BIEditors: Dahut WL, Gulley JL, Moul JW, Sandler HM.Lippincott, Williams, & Wilkins, Philadelphia, PA
• Cancer: Principles & Practice of Oncology. 
  Chapter: Kidney Cancer 
  Linehan M, Rini BI and Yang JCEditors: Drs. Vincent DeVita, Theodore Lawrence, and Steven Rosenberg.Edition 8,
• Manual of Cancer Medicine. 
  Rini BIEditors: Brown CK, Rini BI, Connell PP.BC Decker Inc, Hamilton
• Diseases of the Kidney and Urinary Tract. 
  Chapter: Primary Neoplams of the Kidney and Renal Pelvis 
  Rini BI, Ward J, Vogelzang NJLippincott Williams and WilkinsEdition 8,
• Prostate Cancer. 
  Chapter: Adjuvant Hormonal Therapy for Prostate Cancer 
  Page 464 - 473Rini BI, Vogelzang NJEditors: D’Amico A, Carroll P, Kantoff PW.Lippincott, Williams & Wilkins, Philadelphia, PA
• Everyone’s Guide to Cancer Therapy. 
  Chapter: Kidney Cancer 
  Page 582 - 588Rini BI, Torti FM and Small ESEditors: Dollinger M.Andrews McMeel, Kansas City, MO
• Join now to see all

Abstracts/Posters

• An observational study of metastatic renal cell carcinoma patients prior to initiation of initial systemic therapy.
  Elizabeth R. Plimack, Cheryl Nemec, Paul Elson, Cristina Suarez, Tanya B Dorff, James M. G. Larkin, Cecilia McAleer, Isaac Nunez, Rosalie Anne Fisher, and Brian I. Rini, Asco Meeting Abstract
• Phase III AXIS trial of axitinib versus sorafenib in metastatic renal cell carcinoma: Updated results among cytokine-treated patients.
  M. Dror Michaelson, Brian I. Rini, Bernard J. Escudier, Joseph Clark, Bruce Redman, Jamal Christo Tarazi, Brad Rosbrook, Sinil Kim, and Robert John Motzer, Asco Meeting Abstracts May 30, 2012:4546
• Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma (mRCC) treated with targeted therapy: Results from the International mRCC Data...
  Wanling Xie, Toni K. Choueiri, Jae-Lyun Lee, Lauren Christine Harshman, Georg A. Bjarnason, Jennifer J. Knox, Mary J. MacKenzie, Lori Wood, Ulka N. Vaishampayan, Takes..., Asco Meeting Abstracts May 30, 2012:4538
• A phase II study of intermittent sunitinib in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC).
  Laura S. Wood, Robert Dreicer, Jorge A. Garcia, Timothy D. Gilligan, Khaled B. Ali, Housam Haddad, Shetal N. Shah, Paul Elson, and Brian I. Rini, Asco Meeting Abstracts May 30, 2012:TPS4684
• An in-depth multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clini...
  Daniel Yick Chin Heng, Toni K. Choueiri, Jae-Lyun Lee, Lauren Christine Harshman, Georg A. Bjarnason, Jennifer J. Knox, Mary J. MacKenzie, Ulka N. Vaishampayan, Takesh..., Asco Meeting Abstracts May 30, 2012:4536
• Post-axitinib systemic therapy in metastatic renal cell carcinoma (mRCC).
  Housam Haddad, Brian I. Rini, Eric Jonasch, Nizar M. Tannir, Robert Dreicer, Jorge A. Garcia, Laura S. Wood, and Paul Elson, Asco Meeting Abstracts May 30, 2012:4609
• The association between the treatment-induced hypertension (Htn) and response to neoadjuvant sunitinib in renal cell carcinoma (RCC).
  Baidehi Maiti, Laura S. Wood, Paul Elson, Jorge A. Garcia, Robert Dreicer, Steven C. Campbell, and Brian I. Rini, Asco Meeting Abstracts May 30, 2012:e15095
• A phase I study of BMS-936558 plus sunitinib or pazopanib in patients with metastatic renal cell carcinoma.
  Hans J. Hammers, Brian I. Rini, Gary R. Hudes, Marc S. Ernstoff, Christian K. Kollmannsberger, Yun Shen, Ian Waxman, and Arindam Dhar, Asco Meeting Abstracts May 30, 2012:TPS2614
• Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study.
  Brian I. Rini, Viktor Grunwald, Mayer N. Fishman, Bohuslav Melichar, Takeshi Ueda, Petr A Karlov, A H. Bair, Ying Chen, Sinil Kim, and Eric Jonasch, Asco Meeting Abstracts May 30, 2012:4503
• Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma:...
  Srinivasan, Ramaprasad, Bottaro, Donald P., Choueiri, Toni K., Vaishampayan, Ulka N., Rosenberg, Jonathan E., Logan, Theodore, Harzstark, Andrea Lynne, Rini, Brian I.,..., Genitourinary Cancers Symposium
• Discrepancy between reported progressive disease per radiology report and treating oncologist tumor measurements in patients with metastatic renal cell carcinoma (mRCC...
  Ali, Khaled B., Shah, Shetal N., Wood, Laura S., Garcia, Jorge A., Dreicer, Robert, Gilligan, Timothy D., Rini. Brian I, Genitourinary Cancers Symposium
• Cytoreductive radical nephrectomy (cRN) and level II-IV inferior vena cava (IVC) thrombectomy for metastatic renal cell carcinoma (mRCC).
  Klink, Joseph C., Westesson, Karin E., Rini, Brian I., Rabets, John C., Campbell, Steven C., Ghoneim, Islam, Stephenson, Andrew J., Krishnamurthi, Venkatesh, Genitourinary Cancers Symposium
• A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC).
  Heng, Daniel Yick Chin, Lee, Jae-Lyun, Harshman, Lauren Christine, Bjarnason, Georg A., Razak, Albiruni R., MacKenzie, Mary J., Wood, Lori, Vaishampayan, Ulka N., Tan,..., Genitourinary Cancers Symposium
• The role of stereotactic radiosurgery in the treatment of renal cell carcinoma patients with five or more brain metastases.
  Mohammadi, Alireza Mohammad, Chao, Samuel T., Rini, Brian I., Garcia, Jorge A., Suh, John H., Angelov, Lilyana, Genitourinary Cancers Symposium
• Conditional survival (CS) for patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy (TT): Result...
  Choueiri, Toni K., Xie, Wanling, Harshman, Lauren Christine, Bjarnason, Georg A., Knox, Jennifer J., MacKenzie, Mary J., Wood, Lori, Vaishampayan, Ulka N., Tan, Min-Ha..., Genitourinary Cancers Symposium
• A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final e...
  Choueiri, Toni K., Vaishampayan, Ulka N., Rosenberg, Jonathan E., Logan, Theodore, Harzstark, Andrea Lynne, Rini, Brian I., Srinivas, Sandy, Adams, Laurel M., Sherman,..., Genitourinary Cancers Symposium
• A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials.
  Heng, Daniel Yick Chin, Choueiri, Toni K. Lee, Jae-Lyun, Harshman, Lauren Christine, Bjarnason, Georg A., Knox, Jennifer J., MacKenzie, Mary J., Vaishampayan, Ulka N.,..., Genitourinary Cancers Symposium
• Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): Effect of prior first-line treatment duration and axitinib dose titration on axitinib effi...
  Rini, Brian I., Escudier, Bernard J., Michaelson, M Dror, Negrier, Sylvie, Gore, Martin Eric, Oudard, Stephane, Clark, Joseph, Tarazi, Jamal Christo, Rosbrook, Brad, K..., Genitourinary Cancers Symposium
• International mRCC Consortium. Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): Clinical characteristics, risk factors, and subsequent therapy.
  Heng, D.Y., MacKenzie, M.J., Vaishampayan, U.N., Knox, J.J., Bjarnason, G.A., Tan, M., Wood, L., Donskov, F., Rini, BI, Choueiri, K, Asco Meeting Abstracts, March 29, 2011:29
• Cessation of VEGF-targeted therapy in patients with metastatic renal cell carcinoma (mRCC): Feasibility and clinical outcome
  Sadeghi, S., Albiges, L., Wood, L.S., Black, S.L., Gilligan, T.D., Dreicer, R., Garcia, J.A., Escudier, B.J., Rini, BI, Asco Meeting Abstracts, March 29, 2011:305
• AMG 386 in combination with sorafenib in patients with metastatic renal cell cancer (mRCC): a randomized, double-blind, placebo-controlled, phase II study.
  Rini, BI, Szczylik, C., Tannir, N.M., Koralewski, P., Tomczak, P., Deptata, A., Kracht, K., Sun, Y., Puhlmann, M., Escudier, B, Asco Meeting Abstracts, March 29, 2011:309
• International mRCC Database Consortium. Efficacy of targeted drug therapy for metastatic renal cell carcinoma in the elderly patient population.
  Khambati, H., Choueiri, T.K. Kollmannsberger, C. K., North, S., Bjarnason, G.A., Vaishampayan, U. N., Wood, L., MacKenzie, M.J., Rini, BI, Heng, D.Y, Asco Meeting Abstracts, March 29, 2011:318
• Brain metastases in patients treated with targeted therapy for metastatic renal cell carcinoma (mRCC).
  Alharbi, H., Choueiri, T.K., Kollmannsberger, C.K., North, S., Mackenzie, M.J., Knox, J.J., Rini, BI, Heng, D.Y, Asco Meeting Abstracts, March 29, 2011. 326
• Role of quantitative gene expression using RT-PCR in the prediction of recurrence risk in resected T1 clear cell renal cell carcinoma (ccRCC).
  Campbell, S., Knezevic, D., Maddala, T., Novotny, W.F., Zhou, M., Aydin, H., Elson, P., Parodi, L., Goddard, A.D., Rini, BI, Asco Meeting Abstracts, March 29, 2011:338
• IMA901 Multipeptide Vaccine Randomized International Phase III Trial: A randomized, controlled study investigating IMA901 multipeptide cancer vaccine in patients recei...
  Rini, BI, Elsen, T., Stenzl, A., Brugger, W., Weinschenk, T., Mahr, A., Fritsche, J., Hilf, N., Mendrzyk, R., Lindner, J., Schmid, A., Kirner, A., Walter, S., Singh, H..., Asco Meeting Abstracts, June 9, 2011:TPS183
• Join now to see all

Lectures

• Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion... 
  2019 ASCO Annual Meeting - 6/1/2019
• Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediat... 
  2019 ASCO Annual Meeting - 6/1/2019
• Cell Carcinoma: Bridging the Gap between Evidence and Clinical Practice. 
  Canton, Ohio
• Pre-surgical Targeted Therapy in RCC. 
  ASCO Genitourinary Cancer Symposium
• Individualized Treatment for Patients with Renal. 
  Mercy Cancer Center
• Antio-Angiogenic Therapy in the Clinic: Where We Are, Where We Are Going and How We Will Get There. 
  Keystone Symposium on Molecular and Cellular Biology, Snowbird, Utah
• Molecular Insights in Renal Cell Carcinoma. 
  Kidney Cancer Association, Chicago, Illinois
• Kidney Cancer: New Advances in Treatment. 
  14th Annual Moll Pavilion Cancer Symposium
• Clinical Applications of Genomic Classification of RCC. 
  American Association for Cancer Research 102nd Annual Meeting
• Multidisciplinary Assessments in Advanced Renal Cell Carcinoma: Translating Evidence Into Practice. 
  ASCO GU Annual Meeting
• AMG386 Alone or in Combination with Sorafenib: Results of a Randomized Phase II Trial. 
  Genitourinary Cancers Symposium
• Switching to mTOR Inhibition vs. Maintaining VEGF Inhibition After VEGF Therapy Failure. 
  Ninth International Kidney Cancer Symposium
• Identification of Prognostic Genomic Markers in Patients with Localized Clear Cell Renal Cell Carcinoma. 
  Karmanos Cancer Institute Grand Rounds
• Sunitinib Re-challenge in metastatic RCC. 
  Genitourinary Cancers Symposium
• Hypertension as a biomarker of clinical outcome with sunitinib in metastatic RCC. 
  Genitourinary Cancers Symposium
• Predictive Biomarkers for Targeted Therapy in Metastatic Renal Carcinoma. 
  UCLA Genitourinary GU Lecture
• Hypertension as a biomarker of efficacy in patients with mRCC treated with Sunitinib. 
  12th Annual Symposium on Anti-Angiogenic Agents
• Individualized Therapy for Metastatic Renal Cell Carcinoma. 
  Dartmouth-Hitchcock Medical Center Grand Rounds
• Management of Advanced Prostate Cancer; Renal Cancer; Management of Advanced Renal Cancer. 
  3rd Annual Perspectives in Genitourinary Oncology
• Clinical Care Options: Master Class on Evolving Evidence & Emerging Treatments: Targeted Agents in Advanced RCC. 
• Molecular Markers of Response & Resistance to VEGFR Inhibitors in RCC. 
  ASCO-NCI-EORTC Annual Meeting
• Treatment Algorithm for Advanced Kidney Cancer. 
  2nd Pavia International Symposium on Advanced Kidney Cancer
• New Directions in the Treatment of Advanced RCC. 
  University of Toronto Grand Rounds, Invited Speaker, Toronto, Canada
• Kidney Cancer: First and Further Lines in mRCC. 
  Educational Cancer Convention Lugano (ECCLU), Lugano, Switzerland
• Genetic and Genomic. 
  Sixth European International Kidney Cancer Symposium, Warsaw, Poland
• Join now to see all

Other

• Kidney cancer: Does hypothyroidism predict clinical outcome? 
  Rini B, Nat Rev Urol. 2011 Jan;8(1):10-1. PMID: 21116300
• Editorial comment. 
  Rini BI, Shah SN, Urology. 2010 May;75(5):1114-5
• Editorial Comment. 
  Campbell SC, Rini BI, J Urol. 182(6):2599-600
• Lapatinib therapy for patients with advanced renal cell carcinoma. 
  Rini BI, Nat Clin Prac Oncol, 5(11):626-7
• Quantifying hypertension in patients with cancer treated with sorafenib. 
  Rini BI, Lancet Oncol. 9(2):86-7
• Commentary: Is sorafenib plus interferon alpha 2b safe and effective in patients with renal cell carcinoma? 
  Rini BI, Nat Clin Prac Urol. 5(3):132-3
• Sorafenib in advanced renal cancer. 
  Rini BI, Drugs 67(3); 484-5
• Guest Commentary on: Stabilization of disease in patients with Metastatic Renal Cell Carcinoma using Sorafenib. 
  Rini BI, Nature Clinical Practice Oncology 3(11): 602-03
• Guest Commentary on Sorafenib in Advanced Renal Cancer. Adis Drug Profile. 
  Rini BI, American Journal of Cancer, 2006; 5(2)
• Management of Hormone-Sensitive Non-Metastatic Prostate Cancer. 
  Rini BI, Sandler HM, Wood DP, Report to the Nation on Prostate Cancer: Focus on Advanced Disease 2005 Professional Edition
• Validation and extension of the Memorial Sloan Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. 
  Rini BI, Nature Clinical Practice Oncology 2(5):2-3
• A Randomized Trial of Bevacizumab, an Anti-Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer. 
  Rini BI, Vogelzang NJ, American Journal of Oncology Review. 3(8): 8-10
• Editorial comments on Management of renal carcinoma. 
  Rini BI, Vogelzang NJ, Oncology 14(1): 29-35
• Join now to see all